Cargando…
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy
BACKGROUND: Recurrent respiratory infections (RRIs) are defined by the presence of at least one of the following criteria: (i) > 6 annual respiratory infections (RIs); (ii) > 1 monthly RIs involving the upper airways from September to April; (iii) > 3 annual RIs involving the lower airways...
Autores principales: | Manti, Sara, Parisi, Giuseppe Fabio, Papale, Maria, Licari, Amelia, Salpietro, Carmelo, Miraglia del Giudice, Michele, Marseglia, Gian Luigi, Leonardi, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126168/ https://www.ncbi.nlm.nih.gov/pubmed/32245500 http://dx.doi.org/10.1186/s13052-020-0798-4 |
Ejemplares similares
-
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for preventing recurrent acute otitis media in children: a real-life clinical experience
por: La Mantia, Ignazio, et al.
Publicado: (2017) -
Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract
por: Bidossi, Alessandro, et al.
Publicado: (2018) -
Putative Microbial Population Shifts Attributable to Nasal Administration of Streptococcus salivarius 24SMBc and Streptococcus oralis 89a
por: De Grandi, Roberta, et al.
Publicado: (2018) -
Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: a multicenter, open-label, randomized controlled trial
por: Parisi, Giuseppe Fabio, et al.
Publicado: (2022) -
Population structure of Streptococcus oralis
por: Do, Thuy, et al.
Publicado: (2009)